
Enrico Berrino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/827083/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond. Seminars in Cancer Biology, 2021, 72, 123-135.	9.6	162
2	Basic principles of biobanking: from biological samples to precision medicine for patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 233-246.	2.8	67
3	The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas. Pathobiology, 2020, 87, 125-142.	3.8	49
4	Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group. Frontiers in Oncology, 2020, 10, 489.	2.8	38
5	Acid-free glyoxal as a substitute of formalin for structural and molecular preservation in tissue samples. PLoS ONE, 2017, 12, e0182965.	2.5	27
6	Cold Formalin Fixation Guarantees DNA Integrity in Formalin Fixed Paraffin Embedded Tissues: Premises for a Better Quality of Diagnostic and Experimental Pathology With a Specific Impact on Breast Cancer. Frontiers in Oncology, 2020, 10, 173.	2.8	22
7	The expression of LINE1â€ <i>MET</i> chimeric transcript identifies a subgroup of aggressive breast cancers. International Journal of Cancer, 2018, 143, 2838-2848.	5.1	21
8	Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine. Cancers, 2019, 11, 519.	3.7	21
9	The Dilemma of HER2 Double-equivocal Breast Carcinomas. American Journal of Surgical Pathology, 2018, 42, 1190-1200.	3.7	20
10	Oxidative DNA damage induces hypomethylation in a compromised base excision repair colorectal tumourigenesis. British Journal of Cancer, 2017, 116, 793-801.	6.4	17
11	Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights. Cancers, 2020, 12, 1519.	3.7	15
12	COVseq is a cost-effective workflow for mass-scale SARS-CoV-2 genomic surveillance. Nature Communications, 2021, 12, 3903.	12.8	14
13	Whole exome sequencing in the differential diagnosis of Diamond-Blackfan anemia: Clinical and molecular study of three patients with novel RPL5 and mosaic RPS19 mutations. Blood Cells, Molecules, and Diseases, 2017, 64, 38-44.	1.4	12
14	Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer. Cancer Research, 2021, 81, 4257-4274.	0.9	11
15	Evaluation of global and intragenic hypomethylation in colorectal adenomas improves patient stratification and colorectal cancer risk prediction. Clinical Epigenetics, 2021, 13, 154.	4.1	11
16	Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors. Npj Precision Oncology, 2022, 6, 15.	5.4	11
17	MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer. ESMO Open, 2020, 5, e000937.	4.5	10
18	Pursuit of Gene Fusions in Daily Practice: Evidence from Real-World Data in Wild-Type and Microsatellite Instable Patients, Cancers, 2021, 13, 3376.	3.7	8

ENRICO BERRINO

#	Article	IF	CITATIONS
19	PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma. Cells, 2020, 9, 442.	4.1	7
20	Colorectal Adenomatous Polyposis: Heterogeneity of Susceptibility Gene Mutations and Phenotypes in a Cohort of Italian Patients. Genetic Testing and Molecular Biomarkers, 2016, 20, 777-785.	0.7	5
21	The ACC melanoma pilot project: "Real-world―evaluation of an NGS platform for molecular characterization of melanoma in Italy Journal of Clinical Oncology, 2019, 37, e14600-e14600.	1.6	Ο
22	Antitumor activity of pazopanib (P) and trametinib (T) in preclinical models of osteosarcoma (OS) Journal of Clinical Oncology, 2019, 37, e22509-e22509.	1.6	0
23	PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas—A Preclinical and Translational Study. Cancers, 2021, 13, 6295.	3.7	Ο
24	The Tumor-Specific Expression of L1 Retrotransposons Independently Correlates with Time to Relapse in Hormone-Negative Breast Cancer Patients. Cells, 2022, 11, 1944.	4.1	0